Corvair
AliveCor, Inc. • Cardiovascular • 06/07/2024
Device Purpose
Corvair is a Software as a Medical Device that leverages deep neural networks to provide healthcare professionals with automated initial interpretations of 4-lead resting ECGs, focusing on rhythm and morphological analysis. The system aims to enhance diagnostic efficiency by offering 35 distinct cardiac determinations and interval measurements as an adjunctive tool for physician review, with its performance validated through extensive nonclinical testing against established ECG datasets.
Summary
Corvair by AliveCor is a Software as a Medical Device (SaMD) designed as an ECG analysis system for healthcare professionals. Its primary purpose is to assist in measuring and interpreting resting diagnostic ECGs by providing an initial automated analysis of rhythm and morphological information. The system analyzes 10-second ECGs requiring only 4 leads (either Leads {I, II, V2, V4} or Leads {I, II, V1, V4}) and delivers its analysis via an Application Program Interface (API) library that can be integrated into target devices. Corvair utilizes several deep neural networks (DNNs), trained on approximately one million 12-Lead ECGs with physician-confirmed diagnoses from a diverse patient population sourced from Emory University Hospital. The device offers two operational modes: Asymptomatic Mode, which optimizes specificity and positive predictive value for general screening, and Symptomatic Mode, which enhances sensitivity for situations where there is a high pre-test probability of specific cardiac conditions. The system provides 35 distinct determinations, comprising 14 rhythm analyses (such as Atrial Fibrillation, Sinus Tachycardia, and various AV blocks) and 21 morphology analyses (including Myocardial Infarction, Hypertrophy, and Wolff-Parkinson-White Syndrome), alongside global ECG measurements like PR, QRS, QT intervals, and heart rate. Notably, Corvair does not perform beat-level analysis, may fail to detect or misidentify certain types of conduction system pacing and demand pacing, does not detect sinus pause, and lacks a specific determination for abnormally short PR intervals, although it does detect WPW. The provisional interpretations generated by Corvair are intended strictly as an adjunct to comprehensive clinical assessment, including history, symptoms, and other test results, and must be reviewed and confirmed by a qualified physician before any clinical decisions are made. The device's effectiveness was established through nonclinical performance testing, which evaluated its analytical outputs against large ECG datasets, including the Common Standards for Quantitative Electrocardiography Standard Database (CSEDB) and a proprietary dataset from a clinical study at the Mayo Clinic, using metrics such as sensitivity, specificity, and positive predictive value.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of Corvair's 4-lead ECG analysis compare to traditional 12-lead ECG analysis systems, particularly for subtle or complex morphological changes not fully captured by the selected leads?; What are the specific performance characteristics (sensitivity, specificity, positive predictive value) of Corvair for each of its 35 determinations across diverse demographic subgroups, especially those underrepresented in the initial training dataset?; Given the reliance on deep neural networks, what is the proposed strategy for ongoing monitoring and mitigation of algorithmic bias or performance drift as patient populations, EGG acquisition hardware, and clinical practices evolve beyond the initial training dataset?; How do the 'Symptomatic Mode' and 'Asymptomatic Mode' algorithmically differ in terms of deep neural network architecture, feature weighting, or output thresholding to achieve their respective balances of sensitivity and specificity?; What are the technical integration requirements and potential challenges for 'target devices' incorporating the Corvair API, particularly concerning data input formatting, real-time processing constraints, cybersecurity, and ensuring consistent display of results and disclaimers to the end-user?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Qualifies as a cyber device under §524B (post-Dec 2023, networked)
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, HBOM, OBOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly